8-K: Qualigen Therapeutics Restructures Marizyme Debt, Secures Assets

Qualigen Therapeutics, Inc. has amended its secured promissory note with Marizyme, Inc., increasing the principal to over $4.45 million and securing the debt with Marizyme's assets.

Summary

• Qualigen Therapeutics, Inc. (the Company) entered into an Amended and Restated Secured Demand Promissory Note (the Amended Note) with Marizyme, Inc. on August 21, 2025.
• The Amended Note amends and restates a prior note from July 12, 2024, which had an original principal of $1,250,000.
• The new principal balance is $4,451,462.18, comprising the outstanding balance of the prior note ($3,775,900.20), accrued unpaid interest ($459,561.98), and an additional advance of $216,000.
• The Amended Note bears interest at 18% per annum, with all accrued interest and the full principal balance due in a single balloon payment on August 21, 2026.
• The Company agreed to conditionally forbear from demanding payment for 365 days, unless an event of default occurs, in which case the interest rate increases by 5% per annum to 23%.
• Marizyme granted Qualigen a security interest in substantially all of its assets, including accounts, equipment, intellectual property, and inventory, to secure the obligations under the Amended Note.
• The Company previously consummated a private placement on July 28, 2025, raising approximately $4.5 million in gross proceeds ($4,257,937.50 net) from the sale of 4,500 shares of Series A-3 Preferred Stock.
• A pro forma balance sheet as of June 30, 2025, reflecting these transactions, shows total shareholders' equity of $3,237,655.
• As of August 27, 2025, the Company believes its total shareholders' equity is more than $2.5 million.

Sentiment

Score: 4

Explanation: While the company secured its loan and raised capital, the substantial increase in the Marizyme debt due to accrued interest and the high-risk nature of that loan (18% interest, forbearance) indicate underlying financial challenges for a key partner. The capital raise provides a temporary boost but doesn't fully offset concerns about the quality of the loan portfolio and the accumulated deficit.

Positives

• The Company secured its significant loan to Marizyme with a security interest in substantially all of Marizyme's assets, enhancing recovery prospects.
• The recent private placement generated $4,257,937.50 in net proceeds, strengthening the Company's cash position.
• The pro forma balance sheet indicates a positive total shareholders' equity of $3,237,655 as of June 30, 2025, and the Company believes it remains above $2.5 million as of the report date.
• The 18% interest rate on the Amended Note is a high return for Qualigen as a lender.

Negatives

• The principal balance of the loan to Marizyme has significantly increased to $4,451,462.18, indicating Marizyme's continued reliance on Qualigen for financing and potentially its own financial distress.
• The loan to Marizyme includes a substantial amount of previously accrued and unpaid interest ($459,561.98), suggesting Marizyme's past difficulty in servicing its debt.
• The conditional forbearance period implies that Marizyme is currently unable to repay the debt, pushing the repayment obligation further into the future.
• The high interest rate of 18% (and 23% upon default) on the Marizyme note, while positive for Qualigen as a lender, also signals a high-risk lending environment for Marizyme.
• The pro forma balance sheet shows a significant accumulated deficit of ($126,761,162), indicating historical losses.

Risks

• **Marizyme Default Risk**: There is a significant risk that Marizyme, Inc. may default on the Amended Note, especially given the prior accrued and unpaid interest and the need for an additional advance.
• **Collateral Value Risk**: The value of the collateral (substantially all of Marizyme's assets) may not be sufficient to cover the full principal and interest of the $4,451,462.18 note in the event of a default and liquidation.
• **Co-Development Venture Success**: The Investment Return from the Co-Development Note is "substantially depends on the success of the venture," introducing uncertainty regarding future revenue streams from this agreement.
• **Liquidity Risk**: While the private placement provided capital, the Company's overall financial health, as indicated by the large accumulated deficit, suggests ongoing liquidity management challenges.
• **High-Risk Lending**: Lending at an 18% interest rate (23% upon default) to Marizyme indicates that Marizyme is perceived as a high-risk borrower, which could reflect negatively on Qualigen's investment strategy.

Future Outlook

The filing indicates that the Investment Return from the Co-Development Note with Marizyme is "substantially depends on the success of the venture in which the proceeds of the Funding Amount are used," suggesting future financial performance is tied to the success of this collaborative project. The Company believes its total shareholders' equity is currently more than $2.5 million.

Management Comments

• "The Company believes the pro forma balance sheet reflects its financial position on a pro forma basis as of June 30, 2025."
• "As of the date of this report, the Company believes its total shareholders equity is more than $2.5 million."

Industry Context

This filing highlights common challenges in the biotechnology and pharmaceutical sectors, particularly for smaller companies like Qualigen Therapeutics. Strategic investments or loans to partners, often with high interest rates, can be a way to support co-development efforts or maintain financial ties in a capital-intensive industry. The need for a significant debt restructuring and the high interest rate on the Marizyme note suggest that Marizyme, a partner, may be facing financial difficulties, which could impact Qualigen's strategic initiatives and potential returns from the co-development venture. The private placement is a typical method for biotech companies to raise capital to fund R&D or operational needs.

Comparison to Industry Standards

• The 18% annual interest rate on the Amended Note, escalating to 23% upon default, is significantly higher than typical commercial lending rates for established companies, indicating a high-risk loan. For comparison, a well-established biotech company might secure debt financing at single-digit interest rates (e.g., 5-10%), while distressed or early-stage companies might face rates in the low to mid-teens. This rate suggests Marizyme, Inc. is perceived as a high credit risk, similar to a venture debt scenario or a company in financial distress.
• The securing of the loan with "substantially all of its assets" by Marizyme is a common practice in high-risk lending or distressed situations, aiming to maximize recovery for the lender (Qualigen) in case of default.
• The private placement of preferred stock is a standard capital-raising mechanism for biotech companies, especially those that may find traditional equity markets challenging due to their stage of development or financial performance. The $4.5 million raised is a modest amount for a biotech company, suggesting it may be for specific operational needs rather than large-scale clinical trials.

Related Party Transactions

• The Amended and Restated Secured Demand Promissory Note and Security Agreement with Marizyme, Inc. is a related party transaction, as Qualigen Therapeutics, Inc. is lending to Marizyme, Inc. and has a co-development agreement with them.

Stakeholder Impact

• **Shareholders**: The private placement of preferred stock could dilute the value of common stock if the preferred shares have conversion rights, though this is not specified. The increased exposure to Marizyme's debt, while secured, introduces risk. The positive shareholders' equity is a good sign, but the large accumulated deficit remains a concern.
• **Creditors**: The Company's improved cash position from the private placement may enhance its ability to meet its own short-term obligations.
• **Marizyme, Inc.**: The additional advance and forbearance provide Marizyme with crucial liquidity and time, but also significantly increase its debt burden to Qualigen.
• **Employees**: No direct impact mentioned.

Next Steps

• Marizyme, Inc. is obligated to make a balloon payment of all principal and accrued interest on the Amended Note by August 21, 2026.
• Marizyme, Inc. is required to provide Qualigen Therapeutics, Inc. with annual operating reports for collateral real property within 45 days after year-end.
• Marizyme, Inc. must remain current on all senior liens against its property to avoid default on the Amended Note.
• Qualigen Therapeutics, Inc. will continue to monitor Marizyme's performance under the Amended Note and Security Agreement.

Key Dates

Recommendation

The filing presents a mixed bag. On one hand, Qualigen has successfully raised capital through a private placement and has strengthened its position as a creditor to Marizyme by securing the loan with Marizyme's assets and negotiating a high interest rate. This provides some financial stability and potential for high returns on the loan. On the other hand, the significant increase in the Marizyme loan's principal, largely due to accrued interest, and the need for a forbearance period, highlight ongoing financial distress at Marizyme, which is a key partner. This introduces considerable risk regarding the ultimate collectability of the loan and the success of the co-development venture. The company's large accumulated deficit also remains a long-term concern. Given these offsetting factors, a "hold" recommendation is appropriate, suggesting investors maintain their current position while closely monitoring Marizyme's financial health and Qualigen's progress in its core business.

Keywords

Qualigen Therapeutics, Marizyme, Promissory Note, Secured Debt, Private Placement, Biotechnology, Pharmaceuticals, SEC Filing, 8-K, Corporate Finance, Debt Restructuring, Security Agreement, Shareholders Equity